title: Acute release of plasminogen activator inhibitor-1 in ST-segment elevation myocardial infarction predicts mortality.
abstract: BACKGROUND
  A few studies have suggested that von Willebrand factor (vWF) or plasminogen activator inhibitor-1 (PAI-1) can be associated with outcomes of acute coronary syndromes. The present study was designed to assess the acute release of these markers in ST-segment elevation myocardial infarction (STEMI) and their relations to death.
  
  
  RESULTS
  In 153 consecutive patients with STEMI, vWF and PAI-1 antigens were measured on admission (H0) and 24 hours later (H24). At 30 days, the death rate was 7.2%. Heart failure (Killip stage > or =3) on admission was present in 13.7% of patients. The acute release of PAI-1 (H24-H0, in ng/mL) and of vWF (H24-H0, in %) was dramatically higher in patients who died than in those who survived (46.9+/-26.3 versus -0.6+/-2.8 ng/mL, P=0.0001 and 65.8+/-20.0% versus 10.0+/-5.1%, P=0.004 for PAI-1 and vWF, respectively) and in patients developing heart failure compared with those without (24.8+/-10.1 versus -1.1+/-3.3 ng/mL, P=0.004 and 47.3+/-11.0% versus 8.1+/-5.6%, P=0.005 for PAI-1 and vWF, respectively). The release of PAI-1 correlated weakly with the left ventricular ejection fraction (R=-0.195, P=0.01) and the peak of troponin (R=0.149, P=0.045). Postangioplasty TIMI-3 flow and the acute release of PAI-1 were the only 2 independent predictors of death at 30 days.
  
  
  CONCLUSIONS
  The acute release of vWF and PAI-1 over the first 24 hours of STEMI is associated with death and heart failure. The acute rise of PAI-1 is also a strong independent predictor of death at 30 days.
authors.affiliation: Institut de Cardiologie, Pitié-Salpêtrière Hospital, Paris, France.
authors.forename: J P
authors.initials: JP
authors.lastname: Collet
authors.forename: G
authors.initials: G
authors.lastname: Montalescot
authors.forename: E
authors.initials: E
authors.lastname: Vicaut
authors.forename: A
authors.initials: A
authors.lastname: Ankri
authors.forename: F
authors.initials: F
authors.lastname: Walylo
authors.forename: C
authors.initials: C
authors.lastname: Lesty
authors.forename: R
authors.initials: R
authors.lastname: Choussat
authors.forename: F
authors.initials: F
authors.lastname: Beygui
authors.forename: M
authors.initials: M
authors.lastname: Borentain
authors.forename: N
authors.initials: N
authors.lastname: Vignolles
authors.forename: D
authors.initials: D
authors.lastname: Thomas
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D015906:Angioplasty, Balloon, Coronary; D015415:Biomarkers; D004562:Electrocardiography; D005260:Female; D005500:Follow-Up Studies; D006333:Heart Failure / Q000097:blood / Q000209:etiology / Q000401:mortality; D006801:Humans; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000097:blood* / Q000175:diagnosis / Q000401:mortality* / Q000628:therapy; D017395:Plasminogen Activator Inhibitor 1 / Q000097:blood*; D011237:Predictive Value of Tests; D018570:Risk Assessment; D015607:Stents; D013318:Stroke Volume; D015996:Survival Rate; D014336:Troponin / Q000097:blood; D014841:von Willebrand Factor / Q000032:analysis
chemical_list: D015415:Biomarkers; D017395:Plasminogen Activator Inhibitor 1; D014336:Troponin; D014841:von Willebrand Factor